Deciphering how early life adiposity influences breast cancer risk using Mendelian randomization

被引:0
|
作者
Marina Vabistsevits
George Davey Smith
Eleanor Sanderson
Tom G. Richardson
Bethan Lloyd-Lewis
Rebecca C. Richmond
机构
[1] University of Bristol,Medical Research Council Integrative Epidemiology Unit at the University of Bristol
[2] Oakfield House,Population Health Sciences, Bristol Medical School
[3] University of Bristol,School of Cellular and Molecular Medicine
[4] Oakfield House,undefined
[5] Novo Nordisk Research Centre,undefined
[6] University of Bristol,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Studies suggest that adiposity in childhood may reduce the risk of breast cancer in later life. The biological mechanism underlying this effect is unclear but is likely to be independent of body size in adulthood. Using a Mendelian randomization framework, we investigate 18 hypothesised mediators of the protective effect of childhood adiposity on later-life breast cancer, including hormonal, reproductive, physical, and glycaemic traits. Our results indicate that, while most of the hypothesised mediators are affected by childhood adiposity, only IGF-1 (OR: 1.08 [1.03: 1.15]), testosterone (total/free/bioavailable ~ OR: 1.12 [1.05: 1.20]), age at menopause (OR: 1.05 [1.03: 1.07]), and age at menarche (OR: 0.92 [0.86: 0.99], direct effect) influence breast cancer risk. However, multivariable Mendelian randomization analysis shows that the protective effect of childhood body size remains unaffected when accounting for these traits (ORs: 0.59–0.67). This suggests that none of the investigated potential mediators strongly contribute to the protective effect of childhood adiposity on breast cancer risk individually. It is plausible, however, that several related traits could collectively mediate the effect when analysed together, and this work provides a compelling foundation for investigating other mediating pathways in future studies.
引用
收藏
相关论文
共 50 条
  • [41] Rho GTPase gene expression and breast cancer risk: a Mendelian randomization analysis
    Kazmi, Nabila
    Robinson, Tim
    Zheng, Jie
    Kar, Siddhartha
    Martin, Richard M.
    Ridley, Anne J.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [42] Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis
    Wen, Yaokai
    Wu, Xiangrong
    Peng, Haoxin
    Li, Caichen
    Jiang, Yu
    Su, Zixuan
    Liang, Hengrui
    Liu, Jun
    He, Jianxing
    Liang, Wenhua
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 799 - 806
  • [43] Identification of circulating metabolites linked to the risk of breast cancer: a mendelian randomization study
    Zhu, Xiaosheng
    Huang, Huai
    Zou, Mengjie
    Luo, Honglin
    Liu, Tianqi
    Zhu, Shaoliang
    Ye, Bin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [44] Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization
    Zhang, Ben
    Shu, Xiao-Ou
    Delahanty, Ryan J.
    Zeng, Chenjie
    Michailidou, Kyriaki
    Bolla, Manjeet K.
    Wang, Qin
    Dennis, Joe
    Wen, Wanqing
    Long, Jirong
    Li, Chun
    Dunning, Alison M.
    Chang-Claude, Jenny
    Shah, Mitul
    Perkins, Barbara J.
    Czene, Kamila
    Darabi, Hatef
    Eriksson, Mikael
    Bojesen, Stig E.
    Nordestgaard, Borge G.
    Nielsen, Sune F.
    Flyger, Henrik
    Lambrechts, Diether
    Neven, Patrick
    Wildiers, Hans
    Floris, Giuseppe
    Schmidt, Marjanka K.
    Rookus, Matti A.
    van den Hurk, Katja
    de Kort, Wim L. A. M.
    Couch, Fergus J.
    Olson, Janet E.
    Hallberg, Emily
    Vachon, Celine
    Rudolph, Anja
    Seibold, Petra
    Flesch-Janys, Dieter
    Peto, Julian
    dos-Santos-Silva, Isabel
    Fletcher, Olivia
    Johnson, Nichola
    Nevanlinna, Heli
    Muranen, Taru A.
    Aittomaki, Kristiina
    Blomqvist, Carl
    Li, Jingmei
    Humphreys, Keith
    Brand, Judith
    Guenel, Pascal
    Truong, Therese
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (11):
  • [45] Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis
    Yaokai Wen
    Xiangrong Wu
    Haoxin Peng
    Caichen Li
    Yu Jiang
    Zixuan Su
    Hengrui Liang
    Jun Liu
    Jianxing He
    Wenhua Liang
    Breast Cancer Research and Treatment, 2021, 185 : 799 - 806
  • [46] Lipid metabolite levels associated with the risk of breast cancer: a Mendelian randomization study
    Zhang, W.
    Zhao, D.
    Huang, H.
    Uddin, H.
    Zhang, Y.
    Yang, H.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 116 - 117
  • [47] Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study
    Dimou, Niki L.
    Papadimitriou, Nikos
    Gill, Dipender
    Christakoudi, Sofia
    Murphy, Neil
    Gunter, Marc J.
    Travis, Ruth C.
    Key, Tim J.
    Fortner, Renee T.
    Haycock, Philip C.
    Lewis, Sarah J.
    Muir, Kenneth
    Martin, Richard M.
    Tsilidis, Konstantinos K.
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2019, 48 (03) : 807 - 816
  • [48] Rho GTPase gene expression and breast cancer risk: a Mendelian randomization analysis
    Nabila Kazmi
    Tim Robinson
    Jie Zheng
    Siddhartha Kar
    Richard M. Martin
    Anne J. Ridley
    Scientific Reports, 12
  • [49] Causal effects of life course adiposity on temporomandibular disorders: A Mendelian randomization study
    Chen, Xin
    Cheng, Zheng
    Xu, Junyu
    Wang, Qianyi
    Zhao, Zhibai
    Jiang, Qianglin
    JOURNAL OF ORAL REHABILITATION, 2024, 51 (02) : 278 - 286
  • [50] Life-course adiposity and severe liver disease: a Mendelian randomization analysis
    Wang, Xinyu
    Wu, Zhiyu
    Lv, Jun
    Yu, Canqing
    Sun, Dianjianyi
    Pei, Pei
    Yang, Ling
    Millwood, Iona Y.
    Walters, Robin
    Chen, Yiping
    Du, Huaidong
    Yuan, Mingqiang
    Schmidt, Dan
    Barnard, Maxim
    Chen, Junshi
    Chen, Zhengming
    Li, Liming
    Pang, Yuanjie
    OBESITY, 2023, 31 (12) : 3077 - 3085